| OAF0306 | Cumulative effect of fear of stigma from health professionals and family/neighbors and health care avoidance among PLHIV in Morocco: Results from the Stigma Index Survey Morocco (2016) | Oral abstract session with live Q&A | F37 |
| OAF0402 | Breaking down human-rights related barriers to HIV and TB services in 20 countries. Soon everywhere? | Oral abstract session with live Q&A | F27 |
| OAF0403 | Utilizing individual level data to assess the relationship between prevalent HIV infection and punitive same sex policies and legal barriers across 10 countries in Sub-Saharan Africa | Oral abstract session with live Q&A | F9 |
| OAF0404 | Early warning signs: Assessing the impact of the expanded Mexico City policy on communities most affected by HIV | Oral abstract session with live Q&A | F1 |
| OAF0405 | Assessing the status of drug rehabilitation practices in selected districts of Nepal, from a health and human rights perspective by MoHA, GoN in partnership with YV FDDR and Mainline Foundation | Oral abstract session with live Q&A | F35 |
| OAF0406 | Assessing a human rights-based approach to HIV in Kenya | Oral abstract session with live Q&A | F27 |
| OAXLB0101 | HPTN083 interim results: Pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM,TGW) | Oral abstract session with live Q&A | C43 |
| OAXLB0102 | Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana | Oral abstract session with live Q&A | B44 |
| OAXLB0104 | The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection | Oral abstract session with live Q&A | B30 |
| OAXLB0105 | The first long-term remission of chronic HIV-1 infection without myeloablation? | Oral abstract session with live Q&A | A18 |